ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $1.08, $0.01 better than the analyst estimate of $1.07. Revenue for the quarter came in at $47.29 million versus the consensus estimate of $52.55 million.

For the full year ended December 31, 2017:

• Record net revenues of $176.8 million, an increase of 37% versus 2016
• GAAP net loss of $1.1 million, including a $13.4 million charge due to the Tax Cuts and Jobs Act
• Diluted GAAP loss per share of $0.09, including $1.16 impact of charge due to the Tax Cuts and Jobs Act
• Adjusted non-GAAP EBITDA of $74.2 million
• Adjusted non-GAAP diluted earnings per share of $3.91

For the fourth quarter 2017:

• Net revenues of $47.3 million, an increase of 24% as compared to the same period in 2016
• GAAP net loss of $9.6 million, including impact of $13.4 million charge due to the Tax Cuts and Jobs Act
• Diluted GAAP loss per share of $0.83, including $1.16 impact of charge due to the Tax Cuts and Jobs Act
• Adjusted non-GAAP EBITDA of $19.7 million
• Adjusted non-GAAP diluted earnings per share of $1.08

Guidance for 2018:

• Net revenues of $212 million to $228 million
• Adjusted non-GAAP EBITDA of $90 million to $100 million
• Adjusted non-GAAP diluted earnings per share of $5.43 to $6.08

GUIDANCE:

ANI Pharma sees FY2018 EPS of $5.43-$6.08, versus the consensus of $4.76.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.